Institute Of Hematology & Blood Diseases Hospital, China

This study looks at 112 people with immune thrombocytopenia (ITP) whose platelet counts didn't improve after standard treatment with rhTPO. After a two-week break, they will either get a higher dose of rhTPO or switch to a different drug called eltrombopag. The goal is to see whi…

This study tests a new treatment called nano CD5-CAR T cells for people with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoma. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that carry the CD5 pro…

This phase 2 trial tests a new drug combination for adults newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. The treatment includes CM336 (a bispecific antibody) plus three other drugs. The study aims to see how many patients achieve deep remi…

This phase 2 trial is testing a new drug called CM336, given alongside standard therapy, for people with high-risk multiple myeloma. The study will include 46 adults aged 18 to 75. The main goal is to see if the combination can reduce cancer cells to very low levels (MRD negativi…

This trial is testing a combination of three chemotherapy drugs—clofarabine, busulfan, and melphalan—given before a stem cell transplant in 30 adults with acute myeloid leukemia (AML) who are in first remission. The goal is to see if this conditioning regimen improves survival an…

This phase 2 trial is testing a new way to treat adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph-negative B-ALL). Instead of standard high-dose chemotherapy, patients receive a mix of low-dose chemo plus several targeted drugs (inotuzumab ozogamici…

This early-stage trial tests a one-time infusion of donor immune cells (CAR-γδT cells) designed to target and destroy faulty B cells in people with severe autoimmune diseases like lupus and scleroderma. The main goal is to check safety and find the right dose in 9 adults whose di…

This early-phase study tests a new treatment called IASO206 for people whose autoimmune hemolytic anemia (AIHA) has not responded to standard therapies. AIHA is a condition where the immune system mistakenly destroys red blood cells, causing fatigue and other symptoms. The study …

This study tests whether giving the drug ruxolitinib early can prevent severe graft-versus-host disease (GvHD) in people getting a stem cell transplant. About 438 adults at intermediate-to-high risk, as identified by a special model called daGOAT, will be enrolled. The goal is to…

This study tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) as a first treatment for people with follicular lymphoma, a slow-growing blood cancer. The goal is to see how well the drugs shrink tumors and how safe they are. About 27 newly diagnosed …

This early-phase study tests a new treatment called CY-219 CAR-T cells in 18 people whose B-cell lymphoma has come back or stopped responding to standard care. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The main goals are …

This early study tests a new type of immune cell therapy called Sup19 CAR-T in 9 adults with B-cell acute lymphoblastic leukemia or lymphoma. It is for patients whose cancer stopped responding to previous CD19-targeted treatments or has low levels of CD19. The main goal is to che…

This Phase 3 trial tests whether adding venetoclax to azacitidine as maintenance therapy helps adults with acute myeloid leukemia (AML) stay in remission longer. About 788 patients who achieved first remission after initial treatment will receive either azacitidine alone or azaci…

This early-phase trial tests a new gene therapy called QI-019B for people with multiple myeloma that has returned or not responded to at least two prior treatments. The therapy works by creating cancer-fighting CAR-T cells directly inside the patient's body. The study will enroll…

This early-phase study tests a new drug called SYS6055 in 86 adults whose B-cell cancers (like certain leukemias or lymphomas) have come back or not responded to standard treatments. The main goals are to check safety, find the best dose, and see if it helps shrink tumors or cont…

This study tests whether a three-drug combination (venetoclax, azacitidine, and gilteritinib) followed by strong chemotherapy works better than standard chemotherapy plus gilteritinib for adults with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). About 300 …

This early-phase trial tests a single infusion of CD7 CAR-T cells in 10 children with high-risk T-cell acute lymphoblastic leukemia or lymphoma who have already achieved remission. The goal is to see if this immune cell therapy can safely eliminate remaining cancer cells and redu…

This study tests a drug called gecacitinib in 33 adults who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant and whose condition hasn't improved with steroids. The goal is to find a safe dose and see if it helps control the disease. Participants take th…

This real-world study looks at whether polyene phosphatidylcholine injection can prevent or treat drug-induced liver injury in adults with blood cancers like leukemia and lymphoma. Researchers will review medical records of 1,000 patients to see how well the drug works and if it …

This study tests whether the drug gecacitinib, given before, during, and after a stem cell transplant, can help people with myelofibrosis (a type of bone marrow cancer) have better outcomes. About 39 adults aged 18-75 with intermediate- or high-risk myelofibrosis will take part. …

This study tests if luspatercept can help people with blood cancers who have severe anemia after a stem cell transplant. The goal is to see if the drug reduces the need for red blood cell transfusions. About 20 adults aged 18-60 will take part. This is a phase 2 trial, meaning it…

This study tests whether giving focused, high-dose radiation (SBRT) to tumors outside the bone marrow before a donor stem cell transplant can improve outcomes for adults with blood cancers like leukemia or lymphoma. About 20 participants aged 18-60 will receive this combination t…

This early-phase trial is testing a new type of immune cell therapy called CD19X CAR-T for people with large B-cell lymphoma that has come back or not responded to other treatments. Only 3 participants will receive the therapy after a short course of chemotherapy to prepare their…

This study tests a special chemotherapy combination followed by a single umbilical cord blood transplant in 44 patients aged 60-69 with blood cancers. The goal is to see if this approach is safe and reduces the risk of cancer returning within 180 days. Participants receive severa…

This phase 2 trial tests whether combining olverembatinib (a targeted pill) with inotuzumab ozogamicin (an antibody-drug conjugate) can clear remaining leukemia cells in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who still have detectable …

This study tests a scoring system that uses immune system recovery to decide how long patients should take antiviral medicine after a stem cell transplant. The goal is to prevent a common virus called CMV from causing infection. About 1,114 transplant recipients will take part to…

This study tests a combination of two drugs, pomalidomide and obinutuzumab, in people with slow-growing lymphomas (like follicular lymphoma) that have returned or not responded to prior therapy. The first part finds the safest dose, and the second part checks how well the combina…

This early-stage study tests a new drug, CT1390B, in 18 adults whose acute myeloid leukemia has come back or not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink or clear the cancer. Participants must be bet…

This early study tests a gene therapy called KL003 in just 3 people with severe sickle cell disease. The therapy uses the patient's own stem cells, modified to produce healthy hemoglobin, to reduce painful crises and the need for transfusions. The main goals are to see if the tre…

This early-phase study tests whether giving a bispecific antibody (CM336) before CAR-T cell therapy can improve outcomes for people with relapsed or refractory multiple myeloma — a blood cancer that has stopped responding to standard treatments. Ten adults will receive the antibo…

This early-phase trial tests JY509, a universal natural killer (NK) cell therapy, in 18 children with relapsed or refractory B-cell acute lymphoblastic leukemia. The cells are given as a single injection to see if they are safe and can help control the disease. The study uses a d…

This phase 2 trial tests a bispecific antibody called CM336 as maintenance therapy after stem cell transplant in 20 adults with newly diagnosed multiple myeloma who still have minimal residual disease. The goal is to see if it can clear remaining cancer cells and delay relapse.

This study tests a combination of two newer drugs, blinatumomab and venetoclax, along with standard chemotherapy, for adults with a rare type of leukemia called acute leukemia of ambiguous lineage (ALAL). The goal is to see if this approach improves survival and remission rates. …

This early-phase trial tests a new cell therapy called SL4903 for people with multiple myeloma that has come back or stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified to better attack the cancer. The main goal is to check safety an…

This early-phase trial tests a new treatment called LVIVO-TaVec400 for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to better attack cancer cells. The study will enroll 38 adults…

This study tests a drug called ivarmacitinib to prevent acute graft-versus-host disease (aGVHD) in 32 people with blood cancers receiving a half-matched stem cell transplant. The goal is to see if the drug can lower the chance of severe GVHD and improve survival without long-term…

This early-phase trial tests a personalized treatment called IASO104 for people with relapsed or refractory multiple myeloma, a blood cancer that has not responded to standard therapies. IASO104 is made from a patient's own immune cells, which are genetically modified to recogniz…

This study compares two first-line treatments for severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. One treatment is a stem cell transplant from a half-matched donor, and the other is drug therapy that suppresses the immune system. The stu…

This early study tests a new treatment called IASO206 for people with multiple myeloma that has come back or stopped responding to standard therapies. IASO206 is a type of CAR-T therapy that uses a patient's own immune cells to attack cancer cells. The trial will enroll 12 adults…

This study tests a new drug called golidocitinib, combined with strong immune-suppressing therapy, for people with severe aplastic anemia—a condition where the bone marrow stops making enough blood cells. The trial has two parts: first, it checks safety in patients who didn't imp…

This early study tests a new treatment called CD19 UCAR-T cells for people with autoimmune diseases like lupus, vasculitis, and Sjögren's syndrome. The therapy uses modified immune cells to target and calm the overactive immune system. The main goals are to check safety and see i…

This study tests daratumumab, a drug that targets certain immune cells, in 37 people with aplastic anemia that hasn't improved with standard treatments. The first part checks safety and the right dose, and the second part looks at whether it can improve blood cell counts. The goa…

This study tests whether adding all-trans retinoic acid (ATRA) to the drug avatrombopag can help adults with immune thrombocytopenia (ITP) maintain normal platelet levels without needing ongoing treatment. About 248 participants who have not responded well to first-line therapy o…

This study tests a combination of targeted therapy (zanubrutinib) with a reduced-dose chemotherapy and an antibody drug for people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. About 43 participants will receive four cycles of the combo, then eight mont…

This phase 2 trial tests a new drug called zuberitamab as a first-line treatment for EBV infection in 20 adults who have had a stem cell transplant. EBV can cause a serious complication after transplant, and current treatments don't work for everyone. Zuberitamab is designed to b…

This phase 2 trial tests a reduced-toxicity chemotherapy regimen (thiotepa, melphalan, fludarabine) before a stem cell transplant in 40 people with blast-phase chronic myeloid leukemia (CML), an advanced and hard-to-treat stage. The goal is to see if this gentler approach can imp…

This early-stage study is testing a new treatment called CT1195E CAR-T cells in 30 adults with B-cell blood cancers that have come back or not responded to standard treatments. The therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells…

This early-phase trial tests a two-step treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. First, patients receive special immune cells (CAR-T cells) that target two markers on leukemia cells, followed by a second type …

This early-stage trial will test a new immune cell therapy called CT1194D CAR-T in 20 adults with relapsed or refractory B-cell cancers (lymphoma or leukemia). The main goals are to check safety, find the right dose, and see how long the cells last in the body. Researchers will a…

This early-phase trial tests whether giving a bispecific antibody (QLS32015) before CAR-T cell therapy can improve outcomes for 20 adults with relapsed/refractory multiple myeloma. The study measures how many patients respond and tracks side effects. It is a single-arm, open-labe…

This early-phase study tests whether metformin, a common diabetes drug, can lower the level of a harmful gene mutation (DNMT3A R882) in 30 people with acute leukemia who are in remission. Participants will take metformin pills for 6 months, and researchers will check if the mutat…

This early study tests whether probiotics made from the patient's own or their donor's gut bacteria can improve intestinal health in people with acute graft-versus-host disease (aGVHD) after a stem cell transplant. Ten participants over age 50 will take probiotic capsules and be …

This early-phase trial tests a three-drug combination (ibrutinib, bendamustine, and rituximab) given for a fixed duration in people with Waldenström macroglobulinemia, a rare blood cancer. The study has two parts: first, finding the safest dose of bendamustine, and then testing t…

This early-stage study tests whether specially prepared immune cells from a donor can prevent Epstein-Barr virus (EBV) infection in people who have received a stem cell transplant. About 9 to 18 participants will receive the cells and be monitored for side effects and infection. …

This study looks at blood samples from 1500 stem cell transplant patients to find markers that can predict chronic graft-versus-host disease (cGVHD), a serious complication. Researchers will use mass spectrometry to analyze proteins in the blood and combine this with patient data…

This study will look at how the antifungal drug liposomal amphotericin B behaves in 10 critically ill patients with severe fungal infections who are also receiving plasma exchange therapy. The goal is to understand how plasma exchange changes drug levels in the body, which could …

This study will follow 1,000 adults who have received a stem cell transplant to track a type of antibiotic-resistant bacteria called MBL-CRE. Researchers will use regular swab tests to see how often patients carry these bacteria and how often they develop infections. The goal is …

This study will review medical records of 500 people with newly diagnosed or persistent immune thrombocytopenia (ITP) across multiple hospitals in China. Researchers will look at what treatments patients actually received and how well they worked, without influencing their care. …